2653 Stock Overview
Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Haisco Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.20 |
| 52 Week High | CN¥28.65 |
| 52 Week Low | CN¥18.59 |
| Beta | -0.060 |
| 1 Month Change | 6.74% |
| 3 Month Change | 24.28% |
| 1 Year Change | 6.62% |
| 3 Year Change | 6.29% |
| 5 Year Change | 129.27% |
| Change since IPO | 300.32% |
Recent News & Updates
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well
Mar 19
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Feb 27Shareholder Returns
| 2653 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 11.0% | 0.8% | -0.4% |
| 1Y | 6.6% | -13.4% | -14.4% |
Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 002653 exceeded the CN Market which returned -14.4% over the past year.
Price Volatility
| 2653 volatility | |
|---|---|
| 2653 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002653's share price has been volatile over the past 3 months.
Volatility Over Time: 002653's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5,448 | Xiu Lian Fan | www.haisco.com |
Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular.
Haisco Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 2653 fundamental statistics | |
|---|---|
| Market cap | CN¥31.12b |
| Earnings (TTM) | CN¥358.32m |
| Revenue (TTM) | CN¥3.48b |
86.8x
P/E Ratio8.9x
P/S RatioIs 2653 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2653 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.48b |
| Cost of Revenue | CN¥1.04b |
| Gross Profit | CN¥2.45b |
| Other Expenses | CN¥2.09b |
| Earnings | CN¥358.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 70.25% |
| Net Profit Margin | 10.29% |
| Debt/Equity Ratio | 47.3% |
How did 2653 perform over the long term?
See historical performance and comparison